OSE Immunotherapeutics SA (EPA:OSE)
France · Delayed Price · Currency is EUR | Market Cap | 72.21M -48.8% |
| Revenue (ttm) | 2.69M -93.7% |
| Net Income | -37.69M |
| EPS | -1.69 |
| Shares Out | 23.52M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 196,258 |
| Open | 3.240 |
| Previous Close | 3.212 |
| Day's Range | 3.070 - 3.258 |
| 52-Week Range | 2.872 - 7.700 |
| Beta | 0.83 |
| Analysts | Strong Buy |
| Price Target | 12.70 (+313.68%) |
| Earnings Date | Sep 28, 2026 |
About OSE Immunotherapeutics
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company’s products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical tria... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for OSE stock is "Strong Buy." The 12-month stock price target is €12.70, which is an increase of 313.68% from the latest price.
News
OSE Immunotherapeutics Transcript: Study result
Lusvertikimab, an anti-IL-7 receptor antibody, showed robust efficacy and safety in phase II ulcerative colitis trials, with significant clinical, endoscopic, and histological improvements. Its mechanism and promising results support ongoing development in pouchitis, addressing a major unmet need.
OSE Immunotherapeutics Transcript: Status update
Tedopi, a neoepitope-based immunotherapy, demonstrated improved survival and safety over docetaxel in NSCLC and showed a 50% reduction in progression risk when combined with pembrolizumab in platinum-sensitive ovarian cancer. Rapid adoption is anticipated if phase III results are positive, with further combination strategies under consideration.
OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
First step of a global financing strategy, as the Company is actively engaging with institutional investors in the United States and in Europe Gross proceeds could amount to €19.3 million based on cur...
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer Topline results to be presented by Alexandra Leary, MD, PhD, on May 30, 2026, a...
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi®1 €22.7 and €17.0 million cash position as of December 31, 2025, and M...
OSE Immunotherapeutics Earnings release: H2 2025
OSE Immunotherapeutics released its H2 2025 earnings on April 29, 2026, summarizing the period's financial results.
OSE Immunotherapeutics Annual report: H2 2025
OSE Immunotherapeutics has published its H2 2025 annual report on April 29, 2026.
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
Nantes, France, April 27, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today welcomes the announcement by its partner Veloxis Pharmaceuticals, Inc. that the U.S. Fo...
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
Nantes, France, April 23, 2026 – 7:30am CEST - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-o...
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meet
OSE Immunotherapeutics Evolves its Leadership Team
OSE Immunotherapeutics Evolves its Leadership Team Thomas Gidoin and Aurore Morello appointed Deputy CEO and CSO, respectively Nantes, France, April 14, 2026 – 6:00pm CEST - OSE Immunotherapeutics SA ...
Ose Immunotherapeutics resumed with a Buy at Kepler Cheuvreux
Kepler Cheuvreux resumed coverage of Ose Immunotherapeutics (ORPOF) with a Buy rating and EUR 8.20 price target The firm says the stock trades at a material discount to its sum-of-the-parts
OSE Immunotherapeutics to Present at Upcoming Investor Conferences
Nantes, France, March 23, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-on...
OSE Immunotherapeutics Announces its 2026 Financial Calendar
Nantes, France, March 16, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its financial calendar for 2026. Information Date* 2025 Full-Year Financial...
OSE Immunotherapeutics Confirms Marc Le Bozec As CEO To Drive Next Phase Of Growth
(RTTNews) - OSE Immunotherapeutics SA (OSE) has confirmed Marc Le Bozec from interim to permanent Chief Executive Officer, entrusting him with the company's next phase of strategic expansion.
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®
Streamlining of selected non‑strategic early-stage programs completed, consistent with previously announced three-year 2026-2028 strategic plan No impact on cash runway or financing strategy as no mil...
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab Development built on strong IL-7R biological rationale Chronic Pouchitis offers a...
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) Nantes, France, January 21, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE),...
OSE Immunotherapeutics Transcript: Investor Update
A new management team has launched a strategic plan focused on maximizing value from Tedopi and Lusvertikimab, with four key levers and a balanced financial strategy targeting EUR 90 million over three years. Clinical progress and partnership discussions are ongoing, with a focus on market-driven formulations and rare disease indications.
OSE Immunotherapeutics Press release: Investor Update
OSE Immunotherapeutics issued a press release on December 10, 2025, disclosing material business information to investors.
OSE Immunotherapeutics Unveils 2026-2028 Strategic Plan With Four Value-Creating Opportunities
(RTTNews) - OSE Immunotherapeutics (OSE) has announced a new three-year strategic plan to accelerate late-stage programs while maintaining financial discipline.
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie's Partnership on ABBV-230 Development Strategic Amendment Enhances OSE Immunotherapeutics' Role in ABBV-230 Development While Preserving ...
OSE Immunotherapeutics (ORPOF) Appoints Interim CEO Marc Le Bozec
OSE Immunotherapeutics (ORPOF) Appoints Interim CEO Marc Le Bozec